COVID-19: Jubilant Life Sciences gets DCGI nod for generic version of antiviral drug remdesivir

By: |
Published: July 20, 2020 11:10 PM

Jubilant's remdesivir will be marketed under the brand name 'JUBI-R' in India and will be made available in 100 mg vials (injectable), it added.

COVID-19, coronavirus, Jubilant Life Sciences, COVID-19 drug, coronavirus drug, drug regulator, DCGI, antiviral drug, remdesivir, remdesivir 100 mg/vial, India, Jubilant Generics, Drug Controller General of India, Jubilant remdesivir, Jubilant remdesivir JUBI-R, Gilead remdesivir The company said it is focused on quickly making this drug available in India in required quantities and at affordable prices. (Representational Image)

Jubilant Life Sciences on Monday said it has received drug regulator DCGI approval for generic version of antiviral drug remdesivir 100 mg/vial for restricted emergency use in India for treatment of severe COVID-19.

The company’s subsidiary Jubilant Generics has received the approval from Drug Controller General of India (DCGI) to manufacture and market investigational drug remdesivir 100 mg/vial (lyophilized injection), Jubilant Life Sciences said in a late night filing to BSE.

Jubilant’s remdesivir will be marketed under the brand name ‘JUBI-R’ in India and will be made available in 100 mg vials (injectable), it added.

The company will distribute the drug in the Indian market through its network and it will be available by the first week of August 2020, the filing said.

The company said it is focused on quickly making this drug available in India in required quantities and at affordable prices.

Jubilant Life Sciences, however, did not provide any details about the price of the drug.

In May 2020, Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences Inc that granted it the right to register, manufacture and sell Gilead’s investigational drug remdesivir in 127 countries, including India.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1SC on COVID-19 crisis: Pay pension regularly to eligible elderly, states to provide them medicines, masks, sanitisers
2Unlock 3.0 Delhi rules: Gyms, yoga institutes likely to remain shut in Delhi — check details
3After Amit Shah, Petroleum minister Dharmendra Pradhan tests positive for COVID-19